Evidence for positive selection driving the evolution of HIV-1 env under potent antiviral therapy

Virology

Volumn 284, Issue 2, 2001, Pages 250-258

  Frost, Simon D W ^a,b   Günthard, Huldrych F ^c   Wong, Joseph K ^b,d   Havlir, Diane ^b   Richman, Douglas D ^b   Leigh Brown, Andrew J ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b Division of Infectious Diseases   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Antiviral therapy; env; Evolution; HIV 1; Positive selection

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; INDINAVIR; LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; EVOLUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS ENVELOPE; VIRUS INFECTION; VIRUS ISOLATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0035811212     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0887     Document Type: Article

References (26)

1. Causes of HIV diversity
2. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
3. Development of a quasispecies of human immunodeficiency virus type 1 in vivo
4. Parallel evolution of drug resistance in HIV: Failure of nonsynonymous/synonymous substitution rate ratio to detect selection
5. Rapid, transient changes at the env locus of plasma human immunodeficiency virus
6. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
7. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
8. Codon-based model of nucleotide substitution for protein-coding DNA-sequences
9. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection - 100-Week follow-up
10. Evolution of envelope sequence of HIV-1 in cellular reservoirs in the setting of potent antiviral therapy
11. Residual human immunodeficiency virus-1 RNA and DNA in lymph node and HIV RNA in genital secretions and in cerebrospinal fluid after two years of suppression of viremia in the Merck 035 cohort
12. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences
13. Structure of an HIV gp120 glycoprotein in complex with the CD4 receptor and a neutralising human antibody
14. Divergent patterns of progression to AIDS after infection from the same source: Human immunodeficiency virus type 1 evolution and antiviral responses
15. Evolution of human immunodeficiency virus type 1 env sequence variation in patients with diverse rates of disease progression and T cell function
16. Variances of the average numbers of nucleotide substitutions within and between populations
17. Likelihood models for detecting positively selected amino acid sites and applications to the HIV-1 envelope gene
18. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease inhibitor therapy
19. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
20. Detecting hypermutations in viral sequences with an emphasis on G → A hypermutation
21. Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1
22. HIV-1 genomic RNA diversification following sexual and parenteral virus transmission
23. Recovery of replication competent HIV despite prolonged suppression of plasma viremia
24. Evolutionary mechanisms and population dynamics of the third variable envelope region of HIV within single hosts
25. Reevaluation of amino acid variability of the human immunodeficiency virus type 1 gp120 envelope glycoprotein and prediction of new discontinuous epitopes
26. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy